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Subclinical dermal involvement is
detectable by high frequency ultrasound
even in patients with limited cutaneous
systemic sclerosis
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Abstract
Background: The aim of the study was to detect by skin high-frequency ultrasound (US) possible subclinical skin
involvement in patients affected by limited cutaneous systemic sclerosis (lcSSc), in those skin areas apparently not
affected by the disease on the basis of a normal modified Rodnan skin score (mRSS). Differences in dermal
thickness (DT) in comparison with healthy subjects were investigated.
Methods: Fifty patients with lcSSc (age 62 ± 13 years (mean ± SD), disease duration 5 ± 5 years) and 50 sex-matched
and age-matched healthy subjects (age 62 ± 11 years) were enrolled. DT was evaluated by both mRSS and US at the
usual 17 skin areas (zygoma, fingers, dorsum of the hands, forearms, upper arms, chest, abdomen, thighs, lower legs
and feet). Non-parametric tests were used for the statistical analysis.
Results: Subclinical dermal involvement was detected by US even in the skin areas in patients with lcSSc, who had a
normal local mRSS. In addition, statistically significantly higher mean DT was found in almost all skin areas, when
compared to healthy subjects (p < 0.0001 for all areas). In particular, DT was significantly greater in patients with lcSSc
than in healthy subjects in four out of six skin areas with a normal mRSS (score = 0) (upper arm, chest and abdomen),
despite the clinical classification of lcSSc.
Conclusions: This study strongly suggests that subclinical dermal involvement may be detectable by US even
in skin areas with a normal mRSS in patients classified as having lcSSc. This should be taken into account
during SSc subset classification in clinical studies/trials.
Keywords: Systemic sclerosis, Dermal thickness, High-frequency ultrasound, Rodnan skin score, Nailfold
videocapillaroscopy
Background
Systemic sclerosis (SSc) is a connective tissue disorder
characterized in the early stages by microvascular dam-
age, with progressive fibrosis and skin impairment, the
latter being a marker for disease classification and ac-
tivity [1–6]. Skin involvement may be recognized and
studied using the modified Rodnan skin score (mRSS),
the validated method used to evaluate the severity of
skin thickening in SSc, and to distinguish between
patients with either limited (lcSSc) or diffuse (dcSSc)
cutaneous involvement [2–4, 7]. As per definition, the
affected skin is confined to the extremities (hands, fore-
arms, feet, lower legs and face) in lcSSc, whilst it is also
present on upper arms, chest, abdomen and thighs in
dcSSc [4].
The mRSS has some drawbacks, as it is unable to
identify slight alterations in skin thickness and has high
intra-observer and inter-observer variability [3, 8–10].
Conversely, several studies report the utility of high-
frequency ultrasound (US) for early identification of skin
involvement in patients with SSc [11–15]. US may
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identify the different skin layers and offers a wide range
of values for measurement of dermal thickness (DT),
compared with the semi-quantitative mRSS scale com-
prising only 4 integer values. However, mRSS and US
do not measure exactly the same properties of the skin.
The mRSS measures skin thickness, texture and fix-
ation, while US accurately measures the DT, even if it is
difficult to differentiate between oedema and fibrosis
[11, 16, 17].
The aim of this study was to use US to detect possible
subclinical skin involvement in patients with lcSSc, in
those skin areas apparently not affected on the basis of a
normal local mRSS, looking for differences in DT in
comparison with healthy subjects.
Methods
Study population
Fifty patients with lcSSc (age 62 ± 13 (mean ± SD) years,
mean disease duration 5 ± 5 years), classified on the basis
of a normal mRSS (score = 0) at the upper arms, chest,
abdomen and thighs, were enrolled during routine clin-
ical follow up [7]. Patients with SSc met either the
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) 2013 criteria for
SSc, or the LeRoy’s criteria for the classification of early
SSc, and gave written informed consent to enter the
study [1, 4]. Ethics approval was obtained from the local
ethical board. Complete medical history was recorded,
and clinical examination was carried out in all patients
(the most important clinical findings are reported in
Table 1).
Treatments received by patients included mainly aspirin,
vasodilators, immunomodulatory drugs and endothelin-1
receptor inhibitors; there were no restriction criteria
related to therapy for inclusion of patients in the study,
due to the cross-sectional nature of the investigation and
the limited presence of possible bias in the primary
endpoint.
Fifty sex-matched and age-matched healthy control
subjects (CNT) (mean age ± SD 62 ± 13 years) were also
evaluated after giving informed consent. US was per-
formed in both patients with SSc and in healthy sub-
jects, as described subsequently. Patients and healthy
subjects with presence of lower extremity oedema,
which could confound both mRSS and US assessment,
were excluded.
Skin high-frequency ultrasound
Skin US was performed in both patients with lcSSc and
in healthy subjects to measure DT at the level of all 17
skin areas that are evaluated by the mRSS (at exactly the
same spots), and the values were recorded in millimetres
[12, 13] (see Fig. 1).
An ultrasound system equipped with an 18-MHz
probe was used (MyLab 25, Esaote, Genoa, Italy). A
high-frequency probe offers considerably good reso-
lution, allowing the distinction between the epidermis,
dermis and subcutaneous layers of skin, and measure-
ment of DT [18]. In particular, DT was measured on the
B-mode image by an electronic caliper included with the
software, identifying the upper surface epidermis-dermis
and the lower layer dermis-subcutis [12]. The same op-
erator (BR) performed the US evaluations in all individ-
uals, blinded to the mRSS.
Modified Rodnan skin score
The severity of skin involvement was quantified by the
mRSS in each individual. It was performed in the
Table 1 Clinical findings in patients with systemic sclerosis (SSc) and healthy control subjects (CNT)
Age
(years)
BMI
(kg/m2)
ANA pattern
(cen/spe + nuc/spe)
ENA
(Scl70/RNAP/neg)
RP duration
(years)
SSc duration
(years)
MES
(score)
US-DT total
(mm)
mRSS total
(score)
CNT (n = 50)
mean ± SD
64.9 ± 15.1 22.3 ± 1.9 - - - - 0 14.7 ± 0.5 0
lcSSc (n = 50)
mean ± SD
62.5 ± 12.7 22.4 ± 1.8 33/11/6 11/1/5 12.1 ± 11.6 5.3 ± 4.9 3.2 ± 2.5 17.2 ± 1.7 4.8 ± 2.6
SSc vs CNT
p value*
n.s. n.s. - - - - - <0.0001 <0.0001
Early (n = 21)
mean ± SD
61.3 ± 12.8 22.3 ± 2.0 14/5/2 5/0/2 6.6 ± 4.5 3.1 ± 3.5 0.7 ± 0.5 16.2 ± 1.0 3.2 ± 1.8
Active (n = 16)
mean ± SD
58.6 ± 9.6 22.1 ± 1.5 12/2/2 3/1/0 13.0 ± 13.4 4.3 ± 3.7 4.4 ± 1.3 17.7 ± 1.2 5.0 ± 2.2
Late (n = 13)
mean ± SD
69.2 ± 14.0 23.0 ± 2.3 7/4/2 3/0/3 20.0 ± 13.0 10.0 ± 5.0 6.0 ± 1.1 18.2 ± 2.0 7.3 ± 2.4
E vs A vs L
p value**
n.s. n.s. n.s. n.s. 0.002 0.0002 <0.0001 0.0005 <0.0001
RP Raynaud’s phenomenon, MES microangiopathy evolution score, DT dermal thickness (ultrasound evaluation), mRSS modified Rodnan skin score, SD standard
deviation, E Early, A Active, L Late (patterns of microangiopathy on nailfold videocapillaroscopy), lcSSc limited cutaneous systemic sclerosis, BMI body mass index,
ANA antinuclear antibodies, cen centromeric, spe + nuc speckled and nucleolar, spe speckled, ENA extractable nuclear antigen antibodies, Scl70 anti-topoisomerase
antibodies, RNAP anti-RNA polymerase III autoantibodies, neg ENA-negative. *Mann-Withney U test. **Kruskal-Wallis test
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codified seventeen skin areas (zygoma, fingers, dorsum
of the hands, forearms, upper arms, chest, abdomen,
thighs, lower legs and feet) [7]. Skin thickness was
assessed by palpation, and marked on a scale as 0 (nor-
mal), 1 (weak), 2 (intermediate) or 3 (severe skin thick-
ening). In this study only patients classified as affected
by lcSSc were enrolled (mRSS = 0 at the arms, chest,
abdomen and thighs). The same operator (SP) assessed
the mRSS in all subjects, blinded to the US assessment.
Both mRSS and US were performed the same day in all
patients with SSc.
Nailfold videocapillaroscopy
Nailfold videocapillaroscopy (NVC) was performed using
an optical probe, equipped with a × 200 contact lens,
connected to image analysis software (Videocap, DS
Medica, Milan, Italy) to classify patients with SSc into
the proper pattern of microangiopathy (as early, active
or late), and to calculate the microangiopathy evolution
score (MES), as previously reported [19–22]. The same
operator (CP) performed all NVC evaluations.
Statistical analysis
Non-parametric tests were used for the statistical ana-
lysis. In particular, the Mann-Whitney U test was per-
formed to compare unpaired groups of variables, and
the Kruskal-Wallis test was used to compare continuous
variables with nominal variables with more than two
levels. The Spearman rank correlation test was employed
to identify relationships between variables, along with
linear regression tests. P values lower than 0.05 were
considered statistically significant. The results are re-
ported as mean with standard deviation (SD) and confi-
dence intervals (CI).
Results
The clinical features of patients with SSc and healthy
subjects are reported in Table 1. Subclinical dermal in-
volvement was detected by US even in areas of skin
areas in patients with lcSSc who had local normal mRSS
in those areas. When compared with healthy subjects,
patients with lcSSc had a statistically significant higher
mean DT in all skin areas (p < 0.0001 for all) except the
thighs, where DT was greater in patients with lcSSc than
in healthy subjects but the difference was not statistically
significant (p = 0.16 and p = 0.14, respectively for the
right and left thigh) (see Table 2 and Fig. 2 for further
statistical data).
Of interest, DT was also significantly higher in four
out of six skin areas where the mRSS was normal (score
= 0) (upper arms, chest and abdomen). Moreover, at the
level of the upper arms, chest and abdomen the mean
DT in patients with lcSSc was higher than mean DT
plus three standard deviations in the healthy subjects,
and thus was above the normal range (99.73% probabil-
ity) (see Table 2 for CI).
In particular, almost 75% of patients with SSc had DT
beyond the normal range in the aforementioned skin
areas (instead of the expected 5% of patients allowing
for possible variation from the normal range), despite
their classification as having lcSSc; furthermore, 46–74%
of patients had DT above the 99.73% CI upper limit in
the aforementioned skin areas) (see also Table 2).
As was predictable, the sum of the DT values for the
17 areas of skin assessed by either US or the mRSS was
significantly higher in patients with SSc than in the con-
trol group (Table 1). There was statistically significant
positive correlation between total US-DT and mRSS-DT
values (r = 0.37, p = 0.04).
There was no statistically significant correlation be-
tween DT and the duration of either SSc (p = 0.7) or
Fig. 1 Example of measurement of dermal thickness by skin high-frequency ultrasound (18 MHz probe) in a healthy subject (a) and in a patient
with systemic sclerosis (b) at the level of the abdomen
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Table 2 Dermal thickness in healthy subjects and patients classified as affected by limited cutaneous systemic sclerosis (lcSSc) on
the basis of a normal Rodnan skin score at the upper arms, chest, abdomen and thighs
Dermal thickness Healthy subjects
Patients with
lcSSc
Patients with lcSSc
with DT >2SD
Patients with lcSSc
with DT >3SD
Mean ± SD
(mm)
Mean + 2SD
(mm)
Mean + 3SD
(mm)
95% CI
lower, upper
99.73% CI
lower, upper
Mean ± SD
(mm)
Number (%)
(out of 50)
Number (%)
(out of 50)
Right finger 0.70 ± 0.05 0.80 0.85 0.69, 0.72 0.68, 0.72 0.88 ± 0.14 32 (64) 25 (50)
Left finger 0.70 ± 0.06 0.82 0.88 0.69, 0.72 0.68, 0.72 0.88 ± 0.14 32 (64) 28 (56)
Right hand 0.71 ± 0.06 0.83 0.89 0.69, 0.72 0.68, 0.73 0.84 ± 0.12 23 (46) 13 (26)
Left hand 0.71 ± 0.06 0.83 0.89 0.69, 0.73 0.69, 0.74 0.86 ± 0.16 24 (48) 18 (36)
Right forearm 0.77 ± 0.05 0.87 0.92 0.75, 0.78 0.75, 0.79 0.98 ± 0.19 32 (64) 28 (56)
Left forearm 0.77 ± 0.05 0.87 0.92 0.75, 0.78 0.75, 0.79 0.99 ± 0.19 34 (68) 30 (60)
Right upper arm 0.82 ± 0.07 0.96 1.03 0.80, 0.83 0.79, 0.84 1.06 ± 0.16 37 (74) 23 (46)
Left upper arm 0.82 ± 0.06 0.94 1.00 0.80, 0.83 0.79, 0.84 1.07 ± 0.16 39 (78) 25 (50)
Chest 1.11 ± 0.03 1.17 1.20 1.11, 1.12 1.10, 1.13 1.23 ± 0.17 35 (70) 24 (48)
Abdomen 1.11 ± 0.02 1.15 1.17 1.11, 1.12 1.11, 1.12 1.28 ± 0.18 37 (74) 37 (74)
Right thigh 1.13 ± 0.21 1.55 1.76 1.08, 1.18 1.05, 1.21 1.18 ± 0.23 0 0
Left thigh 1.14 ± 0.20 1.54 1.74 1.08, 1.19 1.05, 1.22 1.18 ± 0.23 1 (2) 0
Right lower leg 0.92 ± 0.04 1.00 1.04 0.91, 0.93 0.90, 0.93 1.03 ± 0.13 25 (50) 16 (32)
Left lower leg 0.92 ± 0.05 1.02 1.07 0.90, 0.93 0.90, 0.93 1.03 ± 0.10 21 (42) 16 (32)
Right foot 0.87 ± 0.04 0.95 0.99 0.86, 0.88 0.86, 0.89 0.96 ± 0.13 24 (48) 17 (34)
Left foot 0.88 ± 0.04 0.96 1.00 0.87, 0.89 0.86, 0.89 0.97 ± 0.11 25 (50) 15 (30)
Zygoma 0.66 ± 0.05 0.76 0.81 0.65, 0.67 0.64, 0.68 0.85 ± 0.10 38 (76) 32 (64)
Mean values, standard deviations (SD) and both 95% and 99.73% confidence intervals (CI) are reported. Of interest, patients with lcSSc had dermal thickness (DT)
values greater than the normal range in healthy subjects (see mean +2SD and +3SD, and upper 95% and 99.73% CI reporting, respectively, the 5% and 0.27%
chance that healthy subjects might have a dermal thickness above the range), also in those areas where the mRSS was zero
Fig. 2 Dermal thickness evaluated by skin high-frequency ultrasound (US) in patients with systemic sclerosis (SSc) and healthy control subjects
(CNT) (SSc vs CNT: p < 0.0001 for all, with the exclusion of thigh). Data are presented as box plots for different skin areas, with the 5th, 10th, 50th
(median), 90th, 95th percentiles
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Raynaud’s phenomenon (RP) (p = 0.6). Neither was there
any statistically significant correlation between DT and
organ involvement (gastrointestinal tract, lung, heart,
kidney or occurrence of digital ulcers) in our cohort of
patients with lcSSc.
Patients with lcSSc who were positive for anti-
centromere antibodies had lower DT (17.07 ± 1.65 mm)
than patients with anti-Scl-70 (17.78 ± 1.89 mm) or anti-
RNA polymerase III (19.30 ± 0.0 mm), but the difference
was not statistically significant (p = 0.40) (however the
population was small and unbalanced in terms of the
autoantibody profile). Dermal thickness, as evaluated by
both US and the mRSS, was significantly higher in those
patients with lcSSc who had the “late” pattern of micro-
angiopathy on NVC and an elevated microangiography
evolution score (MES) (see Table 1). The intra-operator
reproducibility was 92% (95%CI 0.87–0.96) for mRSS
and 96% (95% CI 0.94–0.97) for US.
Discussion
The present investigation demonstrates, for the first
time, that skin high frequency US is able to identify sub-
clinical dermal involvement even in the skin areas where
the mRSS is normal, in patients classified as affected by
lcSSc. Skin involvement in SSc is critical for the initial
diagnosis and it also has prognostic relevance [2, 3].
Cutaneous manifestations are clinically recognized and
studied by the mRSS, the validated method to assess the
severity of skin involvement in SSc [5, 7, 9]. The exten-
sion of skin involvement, evaluated by mRSS, is the par-
ameter for classification of the disease into different
subsets, characterized by either limited or diffuse skin
involvement [2, 4]. This classification is largely used in
clinical trials/studies.
Patients with lcSSc may have increased DT at the ex-
tremities, forearms, lower legs and face, but not at the
upper arms, chest, abdomen and thighs, which charac-
terizes the patients affected by dcSSc, as assessed by
mRSS [2, 3, 7]. Therefore, the present US study of the
skin brings important information to be considered
when the patients are classified as being affected by
lcSSc.
The subclinical skin involvement in patients with lcSSc
is further supported in the present study by showing that
mean DT values were beyond the normal DT value of
the sex-matched and age-matched healthy control sub-
jects (calculated as mean DT value plus three standard
deviations, 99.73% CI upper limit): about 50% of indi-
vidual patients had DT values above the 99.73% CI
upper limit, and about 75% above the 95% CI upper
limit (standard normal range) at the arms, chest and
abdomen.
These observations seem to have a genetic and patho-
physiological background, as recent studies carried out
by gene microarray analysis suggested that in patients
with SSc the clinically unaffected skin shares peculiar
gene signatures and pathological aspects, similar to the
overt clinically affected skin [23, 24]. More recently,
clustering analysis revealed two prominent transcrip-
tomes in skin biopsies from patients with SSc: the
keratin and fibro-inflammatory signatures [25]. Inter-
estingly, in both patients with dcSSc and patients with
lcSSc, hyalinised collagen and myofibroblasts were
identified even in skin that was not clinically involved,
without significant differences between lcSSc and con-
trols [26, 27].
Further possible applications of integrating skin US
analysis with the mRSS in patients with SSc could ori-
ginate from the recent observation that the baseline
mRSS was the strongest predictor of skin improvement,
independent of disease duration [28]. These findings also
seem to link to the report that patients with either lcSSc
or dcSSc may display similar organ/laboratory involve-
ment in clinical studies [29–32]. Altogether these reports
seem to suggest that US may identify skin involvement
earlier than the mRSS in apparently unaffected skin
areas in patients with lcSSc. This is also supported by
other studies, which demonstrated that US is able to
identify the oedematous phase preceding palpable skin
involvement in the early stage of SSc [11, 12, 18].
One limitation to the present study might be the small
cohort of enrolled patients, due to having recruitment at
a single centre, and the larger standard deviation in DT
observed in both patients and healthy subjects at the
thighs might justify the absence of statistically significant
differences between the two groups at this level. Further-
more, the US evaluation was made by only one operator,
and so inter-rater reliability was not assessed.
Another limitation might be the 18-MHz probe
employed to assess DT, due to its good but sub-optimal
performance in analysing the skin; modern higher fre-
quency probes (20–24 MHz) may allow easier identifica-
tion of the dermal boundaries, reducing measurement
error. Once again, the greater variation in DT observed
at the thighs might be related to a slightly blurred image
obtained with our 18-MHz probe at this level.
A further limitation may be linked to the fact that the
patients with SSc were analysed without considering
therapeutic management; however, the aim of the
present study was to assess possible subclinical skin in-
volvement in individual patients with lcSSc and on-
going treatments should not influence the results.
Finally, DT may vary at different ages and according to
premenopausal or postmenopausal status [33]; however,
this bias was avoided by enrolling sex-matched and
age-matched subjects.
By considering the capability of US to detect skin in-
volvement in the early and subclinical stages of SSc, skin
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US might be proposed as a further important tool for
the clinical assessment of the disease. Of note, skin US
may be considered a notable and acceptable technique
for clinical research into the pathogenesis of the disease
and treatment effects, as it represents a non-invasive
and safe approach [34].
As this was a cross-sectional study, data on future
worsening of DT (evaluated by both the mRSS and US)
or progression from lcSSc to dcSSc are not provided.
Further studies should investigate this matter. In terms
of the feasibility of skin US, it is more time-consuming
than mRSS assessment as it takes about 20–25 minutes
including skin image capture and manipulation to meas-
ure DT. However, the examination is well-accepted by
patients, and it do not imply further expense if the de-
vice is the same already employed to assess musculoskel-
etal apparatus during routine clinical practice.
Conclusions
In conclusion, this study strongly suggests that subclinical
dermal involvement may be detectable by skin high-
frequency ultrasound even in patients classified as having
lcSSc on the basis of the mRSS clinical evaluation. This
should be taken into consideration during subset classifi-
cation in clinical studies/trials.
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